PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8735820-1 1996 The antiplatelet activity of two new nitrocompounds, chemically related to acetylsalicylic acid (NCX 4215 and NCX 4016), was studied in vitro to verify the hypothetical dual action of these drugs. Aspirin 75-95 T cell leukemia homeobox 2 Homo sapiens 97-100 9435549-3 1997 As NO can inhibit neutrophil adherence, it is possible that such a derivative of aspirin (NCX-4016) would exert inhibitory effects on neutrophil adherence and therefore be capable of protecting the stomach against shock-induced gastric damage. Aspirin 81-88 T cell leukemia homeobox 2 Homo sapiens 90-93 8950792-1 1996 We studied in vitro the antiplatelet activity of a new nitroderivative chemically related to acetylsalicylic acid: 2 acetoxybenzoate 2-[1-nitroxy-methyl]-phenyl ester (NCX 4016), in order to identify any effects due to the release of nitric oxide and the blockade of cyclo-oxygenase. Aspirin 93-113 T cell leukemia homeobox 2 Homo sapiens 168-171 10065898-0 1999 In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Aspirin 59-66 T cell leukemia homeobox 2 Homo sapiens 79-82 8735820-4 1996 NCX 4215 and NCX 4016 in a dose-dependent way inhibited also thrombin-induced aggregation of platelets pretreated with acetylsalicylic acid. Aspirin 119-139 T cell leukemia homeobox 2 Homo sapiens 0-3 8735820-4 1996 NCX 4215 and NCX 4016 in a dose-dependent way inhibited also thrombin-induced aggregation of platelets pretreated with acetylsalicylic acid. Aspirin 119-139 T cell leukemia homeobox 2 Homo sapiens 13-16 18492771-0 2008 The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes. Aspirin 40-60 T cell leukemia homeobox 2 Homo sapiens 62-65 20608787-2 2010 A nitroderivate of ASA, 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)-phenyl ester (NCX 4016) was synthesized, which additionally acts through nitric oxide release. Aspirin 19-22 T cell leukemia homeobox 2 Homo sapiens 83-86 18472019-0 2008 NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells. Aspirin 25-45 T cell leukemia homeobox 2 Homo sapiens 0-3 18472019-4 2008 In the present paper, we report the results obtained from in in vitro experimental systems aimed to evaluate the activity and mechanisms of action of the novel NO-releasing aspirin derivative, NCX 4040. Aspirin 173-180 T cell leukemia homeobox 2 Homo sapiens 193-196 20299485-8 2010 On the contrary, pretreatment with the NO donor NCX 4016, alone or in combination with aspirin, suppressed platelet activation induced by acute hyperglycemia (NCX 4016 +10.5 +/- 8.3 s; NCX 4016 plus aspirin: +12.0 +/- 10.7 s, P < 0.05 vs. placebo for both). Aspirin 87-94 T cell leukemia homeobox 2 Homo sapiens 48-51 20299485-8 2010 On the contrary, pretreatment with the NO donor NCX 4016, alone or in combination with aspirin, suppressed platelet activation induced by acute hyperglycemia (NCX 4016 +10.5 +/- 8.3 s; NCX 4016 plus aspirin: +12.0 +/- 10.7 s, P < 0.05 vs. placebo for both). Aspirin 199-206 T cell leukemia homeobox 2 Homo sapiens 48-51 20065114-0 2010 NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes. Aspirin 34-41 T cell leukemia homeobox 2 Homo sapiens 0-3 19341823-6 2009 As we found that ASA at 4-8 mM, NCX 4016 at 400-800 microM and NCX 4040 at 4-8 microM stimulated apoptosis of monocytes and immature MoDC, sub-apoptotic concentrations of ASA (2 mM), NCX 4016 (200 microM) and NCX 4040 (2 microM) were used in experiments. Aspirin 171-174 T cell leukemia homeobox 2 Homo sapiens 32-35 19341823-6 2009 As we found that ASA at 4-8 mM, NCX 4016 at 400-800 microM and NCX 4040 at 4-8 microM stimulated apoptosis of monocytes and immature MoDC, sub-apoptotic concentrations of ASA (2 mM), NCX 4016 (200 microM) and NCX 4040 (2 microM) were used in experiments. Aspirin 171-174 T cell leukemia homeobox 2 Homo sapiens 63-66 19341823-6 2009 As we found that ASA at 4-8 mM, NCX 4016 at 400-800 microM and NCX 4040 at 4-8 microM stimulated apoptosis of monocytes and immature MoDC, sub-apoptotic concentrations of ASA (2 mM), NCX 4016 (200 microM) and NCX 4040 (2 microM) were used in experiments. Aspirin 171-174 T cell leukemia homeobox 2 Homo sapiens 63-66 19341823-6 2009 As we found that ASA at 4-8 mM, NCX 4016 at 400-800 microM and NCX 4040 at 4-8 microM stimulated apoptosis of monocytes and immature MoDC, sub-apoptotic concentrations of ASA (2 mM), NCX 4016 (200 microM) and NCX 4040 (2 microM) were used in experiments. Aspirin 171-174 T cell leukemia homeobox 2 Homo sapiens 63-66 19341823-10 2009 ASA inhibited the expression of CD1a and prevented downregulation of CD14, NCX 4016 stimulated the differentiation of CD1a+CD14+ and CD1a(-)CD14+ cells, whereas NCX 4040 decreased the proportion of CD1a+CD14(-) and increased the frequency of CD1a+CD14+ cells, compared to control. Aspirin 0-3 T cell leukemia homeobox 2 Homo sapiens 75-78 19341823-10 2009 ASA inhibited the expression of CD1a and prevented downregulation of CD14, NCX 4016 stimulated the differentiation of CD1a+CD14+ and CD1a(-)CD14+ cells, whereas NCX 4040 decreased the proportion of CD1a+CD14(-) and increased the frequency of CD1a+CD14+ cells, compared to control. Aspirin 0-3 T cell leukemia homeobox 2 Homo sapiens 161-164 18485921-1 2008 Properties of the NO-ASA family of NO-donating NSAIDs (NO-NSAIDs), notably NCX 4016 (mNO-ASA) and NCX 4040 (pNO-ASA), reported in more than one hundred publications, have included positive preclinical data in cancer chemoprevention and therapy. Aspirin 21-24 T cell leukemia homeobox 2 Homo sapiens 75-78 18485921-1 2008 Properties of the NO-ASA family of NO-donating NSAIDs (NO-NSAIDs), notably NCX 4016 (mNO-ASA) and NCX 4040 (pNO-ASA), reported in more than one hundred publications, have included positive preclinical data in cancer chemoprevention and therapy. Aspirin 21-24 T cell leukemia homeobox 2 Homo sapiens 98-101 18492771-1 2008 NCX 4016 is a nitric oxide (NO)-donating derivative of acetylsalicylic acid. Aspirin 55-75 T cell leukemia homeobox 2 Homo sapiens 0-3 18196976-0 2008 NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Aspirin 32-39 T cell leukemia homeobox 2 Homo sapiens 0-3 18302761-3 2008 The antitumor efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied. Aspirin 75-82 T cell leukemia homeobox 2 Homo sapiens 40-43 18196976-1 2008 We have previously reported the inhibitory effect of NCX-4016, a nitro derivative of aspirin, on the proliferation of cisplatin-resistant human ovarian cancer cells, in vitro (Bratasz et al., Proc Natl Acad Sci USA 2006; 103:3914-9). Aspirin 85-92 T cell leukemia homeobox 2 Homo sapiens 53-56 17760507-1 2007 We recently reported that NCX-4016, a derivative of aspirin containing a nitro moiety that releases nitric oxide (NO) in a sustained fashion in biologic systems, is a potent cytotoxic agent inhibiting the proliferation of cisplatin-resistant human ovarian cancer cells. Aspirin 52-59 T cell leukemia homeobox 2 Homo sapiens 26-29 17334512-0 2007 Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Aspirin 48-55 T cell leukemia homeobox 2 Homo sapiens 14-17 17971198-0 2007 Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. Aspirin 100-107 T cell leukemia homeobox 2 Homo sapiens 59-62 17971198-2 2007 In the present study, we investigated the mechanisms underlying the cytotoxicity of NCX 4040, a novel NO-aspirin with promising antineoplastic action, in in vitro human colon cancer models. Aspirin 105-112 T cell leukemia homeobox 2 Homo sapiens 84-87 17903525-0 2007 Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1). Aspirin 22-29 T cell leukemia homeobox 2 Homo sapiens 31-34 17903525-3 2007 A drug class that fulfills this pharmacologic criterion is nitric oxide-donating aspirin (NCX 4016). Aspirin 81-88 T cell leukemia homeobox 2 Homo sapiens 90-93 17903525-4 2007 METHODS: The effect of administration of the aspirin-nitric oxide adduct, NCX 4016, compared with those of aspirin alone and the nitric oxide donor, morpholinosydnonimine, alone (once daily for 1 month) on thickening of saphenous vein-carotid artery interposition grafts was investigated. Aspirin 45-52 T cell leukemia homeobox 2 Homo sapiens 74-77 17903525-6 2007 Aspirin alone (60 mg x kg(-1) x d(-1)) and morpholinosydnonimine alone (1 mg x kg(-1) x d(-1)), also inhibited neointimal thickness and neointimal area, although they were less potent than NCX 4016. Aspirin 0-7 T cell leukemia homeobox 2 Homo sapiens 189-192 16961726-0 2006 Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Aspirin 86-93 T cell leukemia homeobox 2 Homo sapiens 51-54 16961726-1 2006 NCX 4016, 2-(acetyloxy)benzoic acid 3-[(nitrooxy)methyl]phenyl ester, is a new molecule in which a nitric oxide (NO)-releasing moiety is covalently linked to aspirin. Aspirin 10-35 T cell leukemia homeobox 2 Homo sapiens 0-3 16961726-1 2006 NCX 4016, 2-(acetyloxy)benzoic acid 3-[(nitrooxy)methyl]phenyl ester, is a new molecule in which a nitric oxide (NO)-releasing moiety is covalently linked to aspirin. Aspirin 158-165 T cell leukemia homeobox 2 Homo sapiens 0-3 14762100-0 2004 Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. Aspirin 20-27 T cell leukemia homeobox 2 Homo sapiens 162-165 15358033-0 2004 Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. Aspirin 34-41 T cell leukemia homeobox 2 Homo sapiens 43-46 15358033-2 2004 BACKGROUND: NCX-4016 is an aspirin derivative containing a nitric oxide-releasing moiety that prevents platelet activation and modulates tissue factor (TF) expression and cytokine release from lipopolysaccharide (LPS)-stimulated monocytes. Aspirin 27-34 T cell leukemia homeobox 2 Homo sapiens 12-15 15358033-8 2004 NCX-4016 was not associated with gastric damage, and significantly reduced gastric injury when co-administered with aspirin, although both drugs reduced gastric PGE2 production to the same extent. Aspirin 116-123 T cell leukemia homeobox 2 Homo sapiens 0-3 16497833-0 2006 Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Aspirin 109-116 T cell leukemia homeobox 2 Homo sapiens 77-80 16497833-5 2006 We used NCX-4016 [2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester], a derivative of aspirin containing a nitro group that releases nitric oxide in a sustained fashion for several hours in cells and in vivo, and we studied its cytotoxic efficacy against human ovarian cancer cells (HOCCs). Aspirin 93-100 T cell leukemia homeobox 2 Homo sapiens 8-11 16144976-1 2005 Benzoic acid, 2-(acetyl-oxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), a new drug made by an aspirin molecule linked, through a spacer, to a nitric oxide (NO)-donating moiety, is now under clinical testing for the treatment of atherothrombotic conditions. Aspirin 96-103 T cell leukemia homeobox 2 Homo sapiens 63-66 16144976-6 2005 All the NCX 4016 derivatives containing acetylsalicylic acid inhibited the activity of oCOX-1 and oCOX-2, whereas the deacetylated metabolites and the nitric oxide-donating moiety were inactive. Aspirin 40-60 T cell leukemia homeobox 2 Homo sapiens 8-11 16144976-8 2005 Reversible COX inhibitors (indomethacin) or salicylic acid incubated with the enzyme before NCX 4016 prevent the irreversible inhibition of oCOX-1 by NCX 4016 as well as by aspirin. Aspirin 173-180 T cell leukemia homeobox 2 Homo sapiens 92-95 16144976-9 2005 In conclusion, our data show that NCX 4016 acts as a direct and irreversible inhibitor of COX-1 and that the presence of a spacer and NO-donating moiety in the molecule slows the kinetics of COX-1 inhibition by NCX 4016, compared with aspirin. Aspirin 235-242 T cell leukemia homeobox 2 Homo sapiens 34-37 16144976-9 2005 In conclusion, our data show that NCX 4016 acts as a direct and irreversible inhibitor of COX-1 and that the presence of a spacer and NO-donating moiety in the molecule slows the kinetics of COX-1 inhibition by NCX 4016, compared with aspirin. Aspirin 235-242 T cell leukemia homeobox 2 Homo sapiens 211-214 15240674-1 2004 The 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) is a NO-releasing derivative of aspirin. Aspirin 4-29 T cell leukemia homeobox 2 Homo sapiens 62-65 15240674-1 2004 The 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) is a NO-releasing derivative of aspirin. Aspirin 104-111 T cell leukemia homeobox 2 Homo sapiens 62-65 15240674-3 2004 Exposure of lymphocytes and monocytes to aspirin, 2-(acetyloxy)benzoic acid 3-(hydroxymethyl)phenyl ester (NCX-4017), a non-NO-releasing analog of NCX-4016, and cyclooxygenase inhibitors, reduced PG formation, but has no effect on cytokine/chemokine release. Aspirin 41-48 T cell leukemia homeobox 2 Homo sapiens 107-110 15240674-3 2004 Exposure of lymphocytes and monocytes to aspirin, 2-(acetyloxy)benzoic acid 3-(hydroxymethyl)phenyl ester (NCX-4017), a non-NO-releasing analog of NCX-4016, and cyclooxygenase inhibitors, reduced PG formation, but has no effect on cytokine/chemokine release. Aspirin 41-48 T cell leukemia homeobox 2 Homo sapiens 147-150 14762100-1 2004 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) is a nitric oxide (NO)-releasing derivative of aspirin that inhibits cyclooxygenase (COX) activity and releases NO. Aspirin 115-122 T cell leukemia homeobox 2 Homo sapiens 58-61 14762100-0 2004 Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. Aspirin 104-129 T cell leukemia homeobox 2 Homo sapiens 162-165 14762100-0 2004 Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. Aspirin 176-183 T cell leukemia homeobox 2 Homo sapiens 162-165 14762100-1 2004 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) is a nitric oxide (NO)-releasing derivative of aspirin that inhibits cyclooxygenase (COX) activity and releases NO. Aspirin 0-25 T cell leukemia homeobox 2 Homo sapiens 58-61 14582459-1 2003 NCX-4016 is a nitric oxide-aspirin conjugate non-steroidal anti-inflammatory drug that is under investigation by NicOx for the potential treatment of cardiovascular disorders and colon cancer. Aspirin 27-34 T cell leukemia homeobox 2 Homo sapiens 0-3 14563672-1 2004 Aspirin that has been chemically combined with a nitric oxide (NO) donor (NCX-4016) has been shown to inhibit cyclooxygenase and prostaglandin generation while maintaining the inhibitory effects of aspirin. Aspirin 0-7 T cell leukemia homeobox 2 Homo sapiens 74-77 14563672-1 2004 Aspirin that has been chemically combined with a nitric oxide (NO) donor (NCX-4016) has been shown to inhibit cyclooxygenase and prostaglandin generation while maintaining the inhibitory effects of aspirin. Aspirin 198-205 T cell leukemia homeobox 2 Homo sapiens 74-77 14762891-1 2004 NCX4016 [2-acetoxybenzoic acid 3"-(nitrooxymethyl)phenyl ester] is a recently developed nitrooxy-derivative of aspirin with improved antiinflammatory, analgesic, and antithrombotic activity as well as increased gastrointestinal safety. Aspirin 111-118 T cell leukemia homeobox 2 Homo sapiens 0-3 12960371-3 2003 In the present study, we have examined whether inhibition of COX-2 activity in healthy volunteers taking aspirin exacerbates gastric mucosal injury and if such an effect would be prevented by NCX-4016, a NO-releasing derivative of aspirin. Aspirin 231-238 T cell leukemia homeobox 2 Homo sapiens 192-195 12960371-6 2003 The mean mucosal injury score was 5.8 +/- 1.8 in subjects treated with aspirin and 2.4 +/- 0.7 (P < 0.01 vs. aspirin) in subjects treated with NCX-4016. Aspirin 112-119 T cell leukemia homeobox 2 Homo sapiens 146-149 12738997-0 2003 NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Aspirin 35-42 T cell leukemia homeobox 2 Homo sapiens 0-3 12738997-2 2003 We assessed the cytotoxic activity of a new aspirin derivative, NCX 4016, after different exposure schedules, in three human colon adenocarcinoma cell lines. Aspirin 44-51 T cell leukemia homeobox 2 Homo sapiens 64-67 12738997-9 2003 Our results indicate that NCX 4016 has an in vitro cytostatic activity superior to that of its parental aspirin compound, which makes it a potentially important tumor preventive agent. Aspirin 104-111 T cell leukemia homeobox 2 Homo sapiens 26-29 11046058-3 2000 Here, we tested the hypothesis that NCX-4016, a NO-aspirin derivative, inhibits proinflammatory cytokine release from endotoxin (LPS)-challenged monocytes. Aspirin 51-58 T cell leukemia homeobox 2 Homo sapiens 36-39 12846439-5 2003 In vitro studies have shown that NCX-4016 inhibits platelet aggregation induced by aspirin-sensitive (arachidonic acid) and aspirin-insensitive (thrombin) agonist. Aspirin 124-131 T cell leukemia homeobox 2 Homo sapiens 33-36 12846439-9 2003 Indeed, a 7-day course of NCX-4016 results in 90% reduction of gastric damage caused by equimolar doses of aspirin. Aspirin 107-114 T cell leukemia homeobox 2 Homo sapiens 26-29 12612897-0 2003 Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Aspirin 30-37 T cell leukemia homeobox 2 Homo sapiens 39-42 12612897-1 2003 BACKGROUND AND AIMS: NCX-4016 is a nitric oxide-releasing derivative of aspirin with antiplatelet activity. Aspirin 72-79 T cell leukemia homeobox 2 Homo sapiens 21-24 12207011-1 2002 We investigated the effect of a nitric oxide (NO)-releasing derivative of aspirin (NCX-4016) on a mitochondria-dependent model of apoptosis in human umbilical endothelial cells (HUVEC). Aspirin 74-81 T cell leukemia homeobox 2 Homo sapiens 83-86 12846439-3 2003 NCX-4016 consists of the parent molecule (aspirin) linked to a "spacer" via an ester linkage, which is in turn connected to a nitric oxide-releasing moiety. Aspirin 42-49 T cell leukemia homeobox 2 Homo sapiens 0-3 12846439-4 2003 Both aspirin and nitric oxide moieties of NCX-4016 contribute to its effectiveness, the latter occurring via both cyclic guanosyl monophosphate-dependent and -independent mechanisms. Aspirin 5-12 T cell leukemia homeobox 2 Homo sapiens 42-45 12846439-5 2003 In vitro studies have shown that NCX-4016 inhibits platelet aggregation induced by aspirin-sensitive (arachidonic acid) and aspirin-insensitive (thrombin) agonist. Aspirin 83-90 T cell leukemia homeobox 2 Homo sapiens 33-36 11447266-3 2001 2-(Acetyloxy) benzoic acid 3-(nitrooxymethyl) phenyl ester (NCX-1000) is a chemical entity obtained by adding an NO-releasing moiety to ursodeoxycholic acid (UDCA), a compound that is selectively metabolized by hepatocytes. Aspirin 0-26 T cell leukemia homeobox 2 Homo sapiens 60-63 10968413-10 2000 We describe here that NCX 4016 (65 mg/kg/day) increased prostacyclin and thromboxane A2 production in the infarcted heart muscle, overcoming the inhibitory effects of ASA. Aspirin 167-170 T cell leukemia homeobox 2 Homo sapiens 22-25